After a tough September when the S&P 500 fell by 4.8%, the markets have been showing strength again with the index rising more than 5% in October.
Shares of both Jazz Pharmaceuticals are both down sharply, trading near their 52-week lows, while the S&P 500 is up over 20%.
Biotech company Jazz Pharmaceuticals is a stock I’ve been watching closely since its acquisition of GW Pharmaceuticals earlier this year.
In 2020, Jazz’s revenue of $2.4 billion grew by just 9%; the year before that, the top line rose by 14%.
For the period ended June 30, Jazz got a boost of $109.5 million to its top line from the addition of Epidiolex sales, which are now included in the results.
Whether you’re home or in line, waiting to show your vaccine passport, it’s easy to play one of its popular games to pass the time.
And even if people are playing less amid the reopening economy, Zynga could still increase its revenue by taking advantage of other opportunities to monetize its business.
30, Zynga has anticipated that revenue will come in at $665 million, which would be a 32% increase from the same period last year .
While many of them lowered their price targets after release of Q2 earnings and the drop in gaming activity came to light, the consensus still sees the stock rising to at least $12.